Table 4.
Univariate and multivariate analyses of clinical parameters of PFS of further treatment
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Factors | HR | 95% CI | P | HR | 95% CI | P |
| Gender (female/male) | 0.881 | 0.773–1.004 | 0.057 | 0.882 | 0.641–1.214 | 0.441 |
| Age (< 65/≥ 65) | 1.308 | 0.989–1.730 | 0.060 | 1.130 | 0.847–1.507 | 0.407 |
| Smoking (never/ever) | 0.700 | 0.512–0.957 | 0.025 | 0.849 | 0.574–1.256 | 0.413 |
| ECOG (0–1/2–3) | 0.785 | 0.496–1.244 | 0.319 | |||
| Histology (adenocarcinoma/non‐adenocarcinoma) | 0.771 | 0.492–1.208 | 0.256 | |||
| EGFR mutation | 0.511 | |||||
| 19del/double mutation | 0.593 | 0.188–1.872 | 0.373 | |||
| L858R/double mutation | 0.611 | 0.193–1.933 | 0.402 | |||
| Other/double mutation | 1.129 | 0.252–5.055 | 0.874 | |||
| EGFR‐TKIs | 0.224 | |||||
| Gefitinib/afatinib | 0.552 | 0.203–1.502 | 0.245 | |||
| Erlotinib/afatinib | 0.455 | 0.162–1.280 | 0.136 | |||
| Icotinib/afatinib | 0.672 | 0.239–1.889 | 0.451 | |||
| Treatment line of EGFR‐TKIs (1/≥ 2) | 0.927 | 0.696–1.235 | 0.605 | |||
| Efficacy of EGFR‐TKIs | 0.001 | 0.005 | ||||
| PR/PD | 0.336 | 0.188–0.603 | 0.000 | 0.392 | 0.216–0.712 | 0.002 |
| SD/PD | 0.410 | 0.227–0.740 | 0.003 | 0.500 | 0.273–0.916 | 0.025 |
| If re‐biopsied | 0.123 | |||||
| Re‐biopsy/no re‐biopsy | 0.709 | 0.508–0.989 | 0.043 | |||
| Liquid biopsy/no re‐biopsy | 0.798 | 0.535–1.190 | 0.268 | |||
| TBR | 0.000 | 0.002 | ||||
| T790M+ 3‐TKI+/T790M‐3‐TKI‐ | 0.467 | 0.331–0.659 | 0.000 | 0.520 | 0.364–0.745 | 0.000 |
| T790M + 3‐TKI−/T790M‐3‐TKI‐ | 1.041 | 0.704–1.542 | 0.839 | 1.108 | 0.741–1.657 | 0.618 |
| T790M‐3‐TKI+/T790M‐3‐TKI‐ | 1.053 | 0.516–2.146 | 0.888 | 1.212 | 0.590–2.490 | 0.600 |
ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease; TBR treatment‐based result; TKI, tyrosine kinase inhibitor.